GH Research PLC
GHRS12.785USD
+0.035+0.27%
收盘 12/24, 13:00（美东）报价延迟15分钟
793.05M总市值
亏损市盈率 TTM
关于 GH Research PLC 公司
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is engaged in offering treatment for psychiatric and neurological disorders. The Company's pipeline includes GH001, GH002 and GH003. The Company focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.
GH Research PLC简介
公司代码GHRS
公司名称GH Research PLC
上市日期Jun 25, 2021
CEOValcheva (Velichka)
员工数量50
证券类型Ordinary Share
年结日Jun 25
公司地址Joshua Dawson House
城市DUBLIN
上市交易所NASDAQ OMX - NASDAQ BASIC
国家Ireland
邮编D02 RY95
电话35314378334
网址
公司代码GHRS
上市日期Jun 25, 2021
CEOValcheva (Velichka)
GH Research PLC公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Florian Schonharting
Mr. Florian Schonharting
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
14.82M
--
Mr. Michael Forer
Mr. Michael Forer
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Ms. Julie Ryan
Ms. Julie Ryan
Vice President - Finance
Vice President - Finance
--
--
Mr. Magnus Halle
Mr. Magnus Halle
Managing Director, Ireland
Managing Director, Ireland
--
--
Mr. Dermot Hanley
Mr. Dermot Hanley
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Duncan Moore, Ph.D.
Dr. Duncan Moore, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Velichka (Villy) Valcheva, M.D.
Dr. Velichka (Villy) Valcheva, M.D.
Chief Executive Officer
Chief Executive Officer
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Florian Schonharting
Mr. Florian Schonharting
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
14.82M
--
Mr. Michael Forer
Mr. Michael Forer
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Ms. Julie Ryan
Ms. Julie Ryan
Vice President - Finance
Vice President - Finance
--
--
Mr. Magnus Halle
Mr. Magnus Halle
Managing Director, Ireland
Managing Director, Ireland
--
--
Mr. Dermot Hanley
Mr. Dermot Hanley
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Duncan Moore, Ph.D.
Dr. Duncan Moore, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 11月16日 周日
更新时间: 11月16日 周日
持股股东
股东类型
持股股东
持股股东
占比
Schonharting (Florian)
23.90%
BVF Partners L.P.
14.23%
Lynx1 Capital Advisors LLC
13.87%
RA Capital Management, LP
12.38%
RTW Investments L.P.
8.98%
其他
26.65%
持股股东
持股股东
占比
Schonharting (Florian)
23.90%
BVF Partners L.P.
14.23%
Lynx1 Capital Advisors LLC
13.87%
RA Capital Management, LP
12.38%
RTW Investments L.P.
8.98%
其他
26.65%
股东类型
持股股东
占比
Individual Investor
26.78%
Investment Advisor
24.87%
Hedge Fund
22.50%
Venture Capital
13.30%
Investment Advisor/Hedge Fund
9.89%
Research Firm
1.24%
Bank and Trust
0.04%
其他
1.38%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
79
43.69M
70.44%
-1.29M
2025Q2
81
63.73M
102.74%
+7.16M
2025Q1
80
63.74M
102.77%
+7.17M
2024Q4
74
51.85M
85.10%
-3.62M
2024Q3
76
51.78M
99.44%
-4.46M
2024Q2
78
51.68M
99.26%
-4.52M
2024Q1
77
50.90M
97.75%
-4.57M
2023Q4
73
50.91M
97.80%
-2.89M
2023Q3
74
50.54M
97.15%
-4.64M
2023Q2
82
51.15M
98.33%
-4.53M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Schonharting (Florian)
14.82M
23.9%
--
--
Dec 31, 2024
BVF Partners L.P.
8.83M
14.23%
--
--
Jun 30, 2025
Lynx1 Capital Advisors LLC
6.75M
10.88%
+303.01K
+4.70%
Jun 30, 2025
RA Capital Management, LP
7.68M
12.38%
+732.05K
+10.54%
Jun 30, 2025
RTW Investments L.P.
5.54M
8.93%
+40.69K
+0.74%
Jun 30, 2025
Fidelity Management & Research Company LLC
5.09M
8.21%
+842.57K
+19.83%
Jun 30, 2025
Cormorant Asset Management, LP
2.01M
3.24%
--
--
Jun 30, 2025
Terwey (Theis)
4.69M
7.57%
-1.50M
-24.16%
Jun 30, 2025
Deep Track Capital LP
2.00M
3.22%
--
--
Jun 30, 2025
Millennium Management LLC
203.65K
0.33%
+203.65K
--
Jun 30, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
AdvisorShares Psychedelics ETF
5.66%
iShares MSCI Ireland ETF
0.87%
Virtus LifeSci Biotech Clinical Trials ETF
0.76%
SPDR S&P International Small Cap ETF
0.02%
ALPS Medical Breakthroughs ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
AdvisorShares Psychedelics ETF
占比5.66%
iShares MSCI Ireland ETF
占比0.87%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.76%
SPDR S&P International Small Cap ETF
占比0.02%
ALPS Medical Breakthroughs ETF
占比0%
Fidelity Nasdaq Composite Index ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
GH Research PLC的前五大股东是谁？
GH Research PLC 的前五大股东如下：
Schonharting (Florian)持有股份：14.82M，占总股份比例：23.90%。
BVF Partners L.P.持有股份：8.83M，占总股份比例：14.23%。
Lynx1 Capital Advisors LLC持有股份：6.75M，占总股份比例：10.88%。
RA Capital Management, LP持有股份：7.68M，占总股份比例：12.38%。
RTW Investments L.P.持有股份：5.54M，占总股份比例：8.93%。
Schonharting (Florian)持有股份：14.82M，占总股份比例：23.90%。
BVF Partners L.P.持有股份：8.83M，占总股份比例：14.23%。
Lynx1 Capital Advisors LLC持有股份：6.75M，占总股份比例：10.88%。
RA Capital Management, LP持有股份：7.68M，占总股份比例：12.38%。
RTW Investments L.P.持有股份：5.54M，占总股份比例：8.93%。
GH Research PLC的前三大股东类型是什么？
GH Research PLC 的前三大股东类型分别是：
Schonharting (Florian)
BVF Partners L.P.
Lynx1 Capital Advisors LLC
Schonharting (Florian)
BVF Partners L.P.
Lynx1 Capital Advisors LLC
有多少机构持有GH Research PLC(GHRS)的股份？
截至2025Q3，共有79家机构持有GH Research PLC的股份，合计持有的股份价值约为43.69M，占公司总股份的70.44%。与2025Q2相比，机构持股有所增加，增幅为-32.30%。
哪个业务部门对GH Research PLC的收入贡献最大？
在--，--业务部门对GH Research PLC的收入贡献最大，创收--，占总收入的--%。
